Drug resistance in colorectal cancer: An epigenetic overview.
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Despite significant progress that has been made in therapies against CRC over the past decades, drug resistance is still a major limitation in CRC treatment. Numerous investigations have unequivocally shown that epigenetic regulation plays an important role in CRC drug resistance because of the high rate of epigenetic alterations in multiple genes during cancer development or drug treatment. Furthermore, the reversibility of epigenetic alterations provides novel therapeutic strategies to overcome drug resistance using small molecules, which can target non-coding RNAs or reverse histone modification and DNA methylation. In this review, we discuss epigenetic regulation in CRC drug resistance and the possible role of preventing or reversing CRC drug resistance using epigenetic therapy in CRC treatment.
['Luo|Maochao|M|', 'Yang|Xingyue|X|', 'Chen|Hai-Ning|HN|', 'Nice|Edouard C|EC|', 'Huang|Canhua|C|']
D015179:Colorectal Neoplasms D019175:DNA Methylation D019008:Drug Resistance, Neoplasm D044127:Epigenesis, Genetic D006657:Histones D006801:Humans D015398:Signal Transduction
Drug resistance Colorectal cancer Histone modification DNA methylation Noncoding RNA